CIK 0001183765
MTEM Molecular Templates, Inc.
Insider trading from SEC Form 4. Last filing Nov 18, 2024.
In brief
Molecular Templates, Inc. (MTEM) has 8 SEC Form 4 filings on file from 8 insiders, the latest filed on Nov 18, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at MTEM. The newest: Target N Biotech V (10% owner) sold $846k of stock on Nov 14, 2024, filed Nov 18, 2024, scored 55 (moderate).
Last 90 days
Signals
Open-market buys and sells at Molecular Templates, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | Target N Biotech V owner sell | $846k 1,279,820 shares | -100% | - |
Transactions
Every row filed, 10 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | Target N Biotech V owner | SOpen-market sale Common Stock | -1,279,820 | $0.66 | $846k | 0 | Nov 18, 2024 |
| Apr 2, 2024 | Target N Biotech V owner | POpen-market purchase Prefunded Warrants (right to buy)derivative | +134,667 | $2.35 | $316k | 134,667 | Nov 18, 2024 |
| Apr 2, 2024 | Target N Biotech V owner | POpen-market purchase Common Warrants (right to buy)derivative | +769,334 | $0.13 | $96k | 769,334 | Nov 18, 2024 |
| Oct 31, 2023 | Maurizio Voi Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +11,333 | $0.00 | $0 | 11,333 | Nov 1, 2023 |
| Oct 27, 2023 | Gabriela Gruia director | AGrant or award Stock Option (right to buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Oct 31, 2023 |
| Oct 27, 2023 | Dave Hoffmann director | AGrant or award Stock Option (right to buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Oct 31, 2023 |
| Oct 27, 2023 | Kevin M. Lalande director, owner | AGrant or award Stock Option (right to buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Oct 31, 2023 |
| Oct 27, 2023 | Jonathan Lanfear director | AGrant or award Stock Option (right to buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Oct 31, 2023 |
| Oct 27, 2023 | Corazon (Corsee) D. Sanders director | AGrant or award Stock Option (right to buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Oct 31, 2023 |
| Oct 27, 2023 | Harold E Selick director | AGrant or award Stock Option (right to buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Oct 31, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Target N Biotech Vowner
- Gabriela Gruiadirector
- Dave Hoffmanndirector
- Kevin M. Lalandedirector, owner
- Jonathan Lanfeardirector
- Harold E Selickdirector
- Corazon (Corsee) D. Sandersdirector
- Maurizio VoiChief Medical Officer
Questions about MTEM
Answered from the filings on this page, as of the latest one.
Are insiders buying MTEM?
No. In the last 90 days no insider at Molecular Templates, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MTEM on the open market?
Target N Biotech V (10% owner) sold $846k of MTEM on Nov 14, 2024 and filed the Form 4 on Nov 18, 2024. InsiderTell scored 55 (moderate).
How many insiders file Form 4 at Molecular Templates, Inc.?
8 people have filed a Form 4 at Molecular Templates, Inc., among them Target N Biotech V (10% owner), Gabriela Gruia (director), Dave Hoffmann (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.